Business Context and Reporting Period
This Form 10-Q covers the quarterly and six-month periods ended June 30, 2012, for BioZone Pharmaceuticals, Inc. (formerly International Surf Resorts, Inc.). The company operates as a contract manufacturer and marketer of over-the-counter drugs, cosmetics, and nutritional supplements, while developing proprietary drug delivery technology. The filing includes a "Going Concern" warning due to accumulated deficits and negative working capital.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2012 | Six Months Ended June 30, 2011 |
|---|---|---|
| Sales (Revenue) | $8,422,186 | $5,007,315 |
| Gross Profit | $3,475,833 | $1,642,551 |
| Gross Margin | 41.3% | 32.8% |
| Net Loss | $(11,248,659) | $(1,111,609) |
| Net Loss Per Share (Basic/Diluted) | $(0.19) | $(0.03) |
| Cash and Cash Equivalents (End of Period) | $174,212 | $1,839,685 |
| Working Capital | $(5,680,030) | Not explicitly stated (Negative) |
| Total Debt (Current + Long Term) | $4,430,061 | Not explicitly stated |
| Derivative Liability | $4,572,341 | $883,619 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased by 68.2% ($3.4 million) compared to the prior year, driven by increased end-user demand and larger order sizes.
- Margin Expansion: Gross profit margin improved from 33% to 41% due to labor efficiency and a shift toward higher-margin products.
- Surge in Net Loss: Net loss increased by 912% to $11.2 million. This is primarily attributed to non-cash interest expenses of $11.4 million related to the amortization of debt discounts and beneficial conversion features (BCF) on new convertible notes issued in 2012.
- Derivative Liability: The fair value of derivative liabilities (warrants) increased significantly to $4.6 million, contributing to the negative working capital position.
- Cash Flow: Operating cash flow used $2.0 million, compared to $0.9 million in the prior period. Financing activities provided $2.1 million through the issuance of convertible notes and common stock.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management states that substantial doubt exists regarding the company's ability to continue as a going concern due to a shareholder deficiency of $3.9 million and negative working capital. Continued operations depend on meeting financing requirements.
- Unusual Items: The massive net loss is largely non-cash, driven by accounting treatments for convertible notes (BCF and warrant liabilities) rather than operational cash burn alone.
- Litigation Risks:
- Daniel Fisher Lawsuit: A former officer sued the company seeking $23 million in damages for wrongful termination and breach of contract. The company has countersued for $2 million and seeks forfeiture of property and cancellation of shares.
- Aphena Pharma: A breach of contract suit involving a purchase order under $190,000; management does not believe this will be material.
- Controls: The company disclosed material weaknesses in internal controls over financial reporting.
- Seasonality: Approximately two-thirds of revenue is generated in the second half of the year due to the nature of cough/cold products.
Investor Verification Checklist
- Debt Structure: Verify the terms and conversion prices of the multiple convertible notes issued in 2012 (February, March, April, June) and the associated warrant liabilities.
- Liquidity Runway: Assess the sufficiency of the $174,212 cash balance against the $10 million+ in current liabilities and the need for further financing.
- Legal Exposure: Monitor the status of the $23 million lawsuit filed by Daniel Fisher and the company's countersuit.
- Revenue Concentration: Note that two customers accounted for 46% of sales in the six-month period, creating concentration risk.
- Share Dilution: Review the impact of cashless warrant exercises and potential conversions on the outstanding share count (69.8 million shares as of August 2012).